T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Xcel Energy
XEL
$48.5B
| $364M | 0.08% |
8,129,090
-3,121,911
| -28% | -$129M |
|
277
SLB Ltd
SLB
$79.7B
| $363M | 0.08% |
4,595,923
+1,474,592
| +47% | +$113M |
|
278
Guidewire Software
GWRE
$14.7B
| $362M | 0.08% |
5,864,901
+353,063
| +6% | +$20.3M |
|
|
ATHN
279
DELISTED
Athenahealth, Inc.
ATHN
| $362M | 0.08% |
2,621,679
-160,268
| -6% | -$21.2M |
|
280
Regency Centers
REG
$13.9B
| $362M | 0.08% |
4,317,651
-124,271
| -3% | -$9.56M |
|
281
Essex Property Trust
ESS
$18.2B
| $355M | 0.08% |
1,555,609
-38,650
| -2% | -$8.63M |
|
282
LyondellBasell Industries
LYB
$20.7B
| $350M | 0.07% |
4,708,513
+4,051,950
| +617% | +$334M |
|
283
Delta Air Lines
DAL
$59.5B
| $350M | 0.07% |
9,618,007
+2,490,486
| +35% | +$106M |
|
284
Accenture
ACN
$110B
| $349M | 0.07% |
3,078,145
+30,525
| +1% | +$3.54M |
|
|
YHOO
285
DELISTED
Yahoo Inc
YHOO
| $346M | 0.07% |
9,209,283
-3,897,456
| -30% | -$144M |
|
286
Viatris
VTRS
$18.7B
| $346M | 0.07% |
7,997,577
-4,870,671
| -38% | -$215M |
|
|
CXO
287
DELISTED
CONCHO RESOURCES INC.
CXO
| $345M | 0.07% |
2,893,957
-1,228,606
| -30% | -$143M |
|
288
McDonald's
MCD
$194B
| $344M | 0.07% |
2,854,440
-7,537
| -0.3% | -$944K |
|
289
Douglas Emmett
DEI
$1.92B
| $341M | 0.07% |
9,612,267
-444,572
| -4% | -$14.6M |
|
290
Factset
FDS
$10.1B
| $340M | 0.07% |
2,106,968
+1,000
| +0% | +$155K |
|
291
Deere & Co
DE
$167B
| $338M | 0.07% |
4,166,191
-261,965
| -6% | -$21.5M |
|
292
GSK
GSK
$102B
| $336M | 0.07% |
6,204,538
+648,646
| +12% | +$34.2M |
|
293
Veeva Systems
VEEV
$38.4B
| $336M | 0.07% |
9,844,533
-1,431,526
| -13% | -$42.5M |
|
294
Toro Company
TTC
$9.41B
| $327M | 0.07% |
7,409,464
-567,550
| -7% | -$24.8M |
|
|
LNKD
295
DELISTED
LinkedIn Corporation
LNKD
| $323M | 0.07% |
1,705,766
-5,647,011
| -77% | -$783M |
|
296
Zillow
Z
$7.68B
| $320M | 0.07% |
8,809,011
-2,736,787
| -24% | -$75.9M |
|
297
Boston Properties
BXP
$10.8B
| $316M | 0.07% |
2,396,816
+49,640
| +2% | +$6.37M |
|
298
Northrop Grumman
NOC
$81.8B
| $311M | 0.07% |
1,398,255
+376,794
| +37% | +$79.3M |
|
299
Murphy Oil
MUR
$5.12B
| $310M | 0.07% |
9,763,270
-1,790,280
| -15% | -$54.1M |
|
300
Teva Pharmaceuticals
TEVA
$42.5B
| $308M | 0.07% |
6,135,191
-269,555
| -4% | -$14.4M |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.